Comparing the current results to its competitors, Altamira Therapeutics Ltd reported Revenue decrease in the 4 quarter 2023 year on year by 0 %, slower than the combined decrease of the CYTO's competitors by -13.2 %, recorded in the same quarter.
Altamira Therapeutics Ltd , slower than the average decrease reported by the company's competitors of -27.87 %. recorded a net loss and most of the company's competitors saw a decline in earnings by -27.87 %
Altamira Therapeutics Ltd 's Comment on Competition and Industry Peers
The company operates in a competitive environment that includes large, fully integrated pharmaceutical companies, specialty pharmaceutical companies, biopharmaceutical companies, academic institutions, government agencies, and other private and public research institutions in Europe, the United States, and other regions. These competitors may have greater resources and engage in similar research activities, seek patent protection, and form collaborative arrangements for research, development, manufacturing, and marketing of products that compete with the company's product candidates. The company depends on an exclusive license agreement with Washington University, which is essential to its business and commercialization efforts. Risks include potential breaches of confidentiality agreements and the possibility that competitors may lawfully obtain or independently develop similar technology or information, potentially affecting the company's competitive position.
August 23, 2024
: Altamira Therapeutics Ltd. is making significant strides in expanding its footprint in the Scandinavian pharmaceutical market with the extension of its distribution agreement for Bentrio, a nasal spray designed for the prevention and treatment of allergic rhinitis. This article outlines the context and potential implications of this expansion, as well as the company s recent stock performance. The management of allergic rhinitis continues to be a pressing concern for healthcare providers and patients alike. In light of growing awareness around the condition and its impact on quality of life, the demand for effective treatment options remains high. Altamira Therapeutics Ltd. (Nasdaq: CYTO) has positioned...
March 25, 2024
Altamira Therapeutics Joins Forces with Univercells Group to Advance Nanoparticle-Delivered mRNA VaccinesHAMILTON, BERMUDA, March 25, 2024 - Altamira Therapeutics Ltd. (Altamira) (Nasdaq:CYTO), a leading provider of nanoparticle-based technology for efficient RNA delivery to extrahepatic targets, has announced a promising collaboration with Univercells Group (Univercells). This partnership aims to assess the effectiveness of Altamira s proprietary SemaPhore platform for the delivery of mRNA vaccines. Univercells, a global life sciences company renowned for creating platforms that enable the development and manufacturing of biologics, including mRNA vaccines and therapeutics in an accessible, scalable, and co...
Biohaven Ltd operates as a pharmaceutical company that focuses on discovering and developing therapies for neurological diseases and rare disorders. Their business model revolves around conducting extensive research and clinical trials to bring innovative treatments to market. By collaborating with healthcare professionals, regulatory agencies, and investors, Biohaven aims to improve the lives of patients suffering from these conditions and provide a significant return on investment for stakeholders.
Legend Biotech Corporation is a biotech company focused on developing innovative cell therapies and gene therapies to address unmet medical needs in various diseases.
TherapeuticsMD Inc is a pharmaceutical company that focuses on developing and commercializing innovative hormone therapy products for women. Their business model revolves around research, development, and marketing of prescription and over-the-counter products catering to women's health needs. By leveraging strategic partnerships and collaborations, they aim to bring their products to market, ultimately improving the quality of life for women.
Inflarx N is a company that operates on a B2B (business-to-business) model. They offer a range of services and products such as software solutions, data analytics, and consulting to businesses in the technology sector. Their revenue primarily comes from subscription fees, licensing, and consulting fees.
Sources:
Altamira Therapeutics Ltd’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Altamira Therapeutics Ltd versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
